423
Participants
Start Date
July 8, 2021
Primary Completion Date
January 12, 2024
Study Completion Date
December 19, 2028
Neoadjuvant ipilimumab + nivolumab
2 cycles ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by total lymph node dissection
Adjuvant nivolumab
Upfront total lymph node dissection followed by 12 cycles of nivolumab (480mg) every 4 weeks.
Melanoma Institute Australia (MIA), Sydney
MD Anderson Cancer Center, Houston
The Angeles Clinic, Los Angeles
Princess Alexandra Hospital, Brisbane
Lake Macquarie Private Hospital, Gateshead
Alfred Health, Melbourne
Peter MacCallum Cancer Center, Melbourne
Fiona Stanley Hospital, Murdoch
Tasman Oncology, Southport
Westmead Hospital, Sydney
Amsterdam University Medical Center - location VUmc, Amsterdam
Amphia Ziekenhuis, Breda
Maxima Medisch Centrum, Eindhoven
Medisch Spectrum Twente, Enschede
University Medical Center Groningen, Groningen
Zuyderland Medisch Centrum, Heerlen
Medisch Centrum Leeuwarden, Leeuwarden
Leiden University Medical Center, Leiden
Maastricht University Medical Center, Maastricht
Radboud University Medical Center, Nijmegen
Erasmus Medical Center, Rotterdam
University Medical Center Utrecht, Utrecht
Isala Hospital, Zwolle
Netherlands Cancer Institute, Amsterdam
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
The Netherlands Cancer Institute
OTHER